| Literature DB >> 35804511 |
Reinhard Sting1,2, Claudia Geiger1,2, Wolfram Rietschel3, Birgit Blazey1, Ingo Schwabe1, Jörg Rau1, Lisa Schneider-Bühl1,2.
Abstract
Alpacas are the major camelid species in Europe held for hobbies, animal-aided therapy, and commercial reasons. As a result, health-related issues associated with alpacas are of growing significance. This especially holds true for one of the most serious infectious diseases, caseous lymphadenitis, which is caused by the bacterial pathogen Corynebacterium (C.) pseudotuberculosis. Our study focuses on post-mortem examinations, the laboratory diagnostic tool ELISA, and the immunoblot technique for the detection of specific antibodies against C. pseudotuberculosis and detection of the causative pathogen in alpaca herds. We examined a total of 232 alpacas living in three herds. Four of these alpacas were submitted for post-mortem examination, revealing abscesses, apostematous and fibrinous inflammation in inner organs, pleura, and peritoneum. Serological investigation using a commercial ELISA based on phospholipase D (PLD) as antigen and an in-lab ELISA based on whole cell antigens (WCA) revealed an overall seroprevalence of 56% and 61.2%, respectively. A total of 247 alpaca sera originating from 232 animals were tested comparatively using the in-lab and the commercial ELISA and showed a substantial degree of agreement, of 89.5% (Cohen's kappa coefficient of 0.784), for both tests. Further comparative serological studies using the two ELISAs and the immunoblot technique were carried out on selected sera originating from 12 breeding stallions and six breeding mares for which epidemiological data and partial C. pseudotuberculosis isolates were available. The results showed the immunoblot to have a sensitivity that was superior to both ELISAs. In this context, it should be emphasized that evaluation of these investigations and the epidemiological data suggest an incubation period of one to two months. Antibiotic susceptibility testing of 13 C. pseudotuberculosis isolates based on the determination of minimal inhibitory concentrations using the broth microdilution method revealed uniform susceptibility to aminopenicillins, cephalosporines, macrolides, enrofloxacin, florfenicol, tetracycline, sulfonamid/trimethoprime, tiamulin, gentamicin, neomycin, spectinomycin, and vancomycin, but resistance to colistin, nitrofurantoin, and oxacillin.Entities:
Keywords: Corynebacterium pseudotuberculosis; ELISA; FT-IR; MALDI-TOF MS; alpaca; antibiotic susceptibility testing; camelid; caseous lymphadenitis; immunoblot; post-mortem examination
Year: 2022 PMID: 35804511 PMCID: PMC9264953 DOI: 10.3390/ani12131612
Source DB: PubMed Journal: Animals (Basel) ISSN: 2076-2615 Impact factor: 3.231
Figure 1Abscess on the upper jaw below the eye caused by C. pseudotuberculosis (stallion S8).
Results of bacteriological and serological examinations on caseous lymphadenitis in selected alpacas in three herds. The name of the C. pseudotuberculosis isolates and the date of isolation are given in brackets in the first column.
| Animal | Herd | Date of Sampling for Serological Testing | Result | Result | Result Immunoblot |
|---|---|---|---|---|---|
| Stallion S1 1,2 euthanized on 14 December 2020 (CVUAS 32834.2) | A | 21 September 2020 | – | + | + |
| Stallion S2 1,3 | A | 21 September2020 | – | + | + |
| Mare M1 2 (CVUAS 32654, 22 September 2020) | A | 22 September 2020 | + | + | + |
| Stallion S3 1,2,4 (CVUAS 32746, 20 October 2020) | B | 20 October2020 | + | + | + |
| Stallion S4 4,5 | B | 20 October 2020 | + | + | + |
| Stallion S5 4,6 | B | 20 October 2020 | + | + | + |
| Stallion S6 4,6 | B | 20 October 2020 | + | + | + |
| Stallion S7 4,6 | B | 20 October 2020 | + | + | + |
| Stallion S8 2 (CVUAS 32830, 9 December 2020) | B | 20 October2020 | – | – | – |
| 9 December 2020 | + | + | + | ||
| 15 April 2021 | + | + | + | ||
| 21 September 2021 | + | + | + | ||
| Stallion S9 2,7 (CVUAS S32745, 20 October 2020) | B | 20 October 2020 | – | + | + |
| 9 December 2020 | + | + | + | ||
| 15 April 2021 | + | + | + | ||
| 21 September 2021 | + | + | + | ||
| Stallion S10 7 | B | 20 October 2020 | – | + | + |
| 9 December 2020 | + | + | + | ||
| 15 April 2021 | + | + | + | ||
| 21 September 2021 | + | + | + | ||
| Stallion S11 7 | B | 20 October 2020 | – | – | +(weak) |
| 9 December 2020 | – | – | +(weak) | ||
| 15 April 2021 | – | – | +(weak) | ||
| Stallion S12 7 | B | 20 October 2020 | – | – | +(weak) |
| 9 December 2020 | – | – | +(weak) | ||
| 15 April 2021 | – | – | +(weak) | ||
| Mare M2 2 died on 16 January 2020 | C | 15 January 2020 | + | + | + |
| Mare M3 2 (CVUAS 9749.2, 6 March 2020) | C | 6 March 2020 | – | – | +(weak) |
| Mare M4 2 (CVUAS 32842, 11 December 2020) | C | 11 December 2020 | + | – | +(weak) |
| Mare M5 2 (CVUAS 32931, 2 February 2021) | C | 8 February 2021 | + | + | + |
| Mare M6 2 (CVUAS 33314, 8 October 2021) | C | 8 October 2021 | – | + | + |
| 3 November 2021 | – | + | + | ||
| 1 December 2021 | + | + | + | ||
| Mare M7 2 died on 10 October 2020 | B | / | n.t. | n.t. | n.t. |
| MareM8 2 euthanized on 24 September 2020 (CVUAS 32656) | A | / | n.t. | n.t. | n.t. |
| Mare M9 2 (CVUAS 32632, 12 September 2020) | A | / | n.t. | n.t. | n.t. |
1 Stallion that had been purchased and simultaneously introduced into herd A in April 2020; 2 Alpaca with abscesses and isolation of C. pseudotuberculosis; 3 Alpaca with abscesses but without bacterial examination; 4 Stallion which had been introduced from herd A into herd B on 21 August 2020; 5 Stallion in poor health condition. 6 Animal without clinical signs. 7 Stallion that had been shorn together in May 2020. N.t. = not tested serologically, only by bacterial examination.
Superficial abscesses and internal abscesses detected by post-mortem examinations. The names of the C. pseudotuberculosis isolates are given in brackets in the first column.
| Animal, Herd | Herd | Date | Visible Abscesses in | Absecces in | |||
|---|---|---|---|---|---|---|---|
| Lungs | Liver | Spleen | Kidney | ||||
| Stallion S1 1 (CVUAS 32834.2) | A | Euthanized on 14 December 2020 | Ln. cervicalis superficialis | − | + | + | − |
| Mare M2 2,3 (CVUAS 32166) | C | Died on 16 January 2020 | Ln. mandibularis, Ln. subiliacus | + | + | − | − |
| Mare M7 1,4,5 (CVUAS 32689) | B | Died on 10 October 2020 | Subcutis of the neck | + | + | + | + |
| Mare M8 (CVUAS 32656) | A | Euthanized on 24 September 2020 | Subcutis of the scapula and abdominal wall | + | − | − | − |
1 fibrinous peritonitis; 2 apostematous pleuritis; 3 apostematous myocarditis; 4 fibrinous pleuritis; 5 apostematous pericarditis; Ln. = lymph node.
Figure 2Immunoblot analyses of 33 blood samples originating from 17 alpacas for detection of antibodies against C. pseudotuberculosis. See Table 1 for details on the alpacas. Immunoblot (A) Stallions S1–S8, mare M1; Immunoblot (B) Stallions S9–S11; Immunoblot (C) Stallion S12, mares M2–M6; Sampling dates: A: January 2020, B: March 2020, C: September 2020, D: October 2020, E: December 2020, F: February 2021, G: April 2021, H: September 2021, I: October 2021, J: November 2021, K: December 2021; M = marker (kDa = kilo Dalton), PC = positive control, NC = negative control.
Figure 3Abscesses in the liver (A) and the spleen (B) of stallion S1. The abscesses were caused by C. pseudotuberculosis and detected during post-mortem examination.
Figure 4Dendrogram of IR-spectra of Corynebacterium (C.) pseudotuberculosis isolates from alpacas in comparison with spectra from dromedaries, llamas, goats and sheep. Isolates of C. ulcerans, C. silvaticum, C. rouxii, C. diphtheriae and C. belfantii were included for differentiation of the corynebacterial species belonging to the C. diphtheriae group.
Determination of minimal inhibitory concentration (MIC) values (mg/L) for C. pseudotuberculosis isolates using the broth microdilution method carried out in microtiter plates. Evaluation of the MIC values was carried out using the MCN6 software (Merlin, Germany). R = resistance, I = intermediary susceptibility, S = susceptibility.
| Antibiotic | MIC | Result | Number of Strains | MIC | Result | Number of Strains |
|---|---|---|---|---|---|---|
| Amoxycillin/Clavulanic acid | ≤2/1 | S | 13 | |||
| Ampicillin | ≤0.25 | S | 13 | |||
| Cefazolin | ≤1 | S | 13 | |||
| Cefoxitin | =4 | S | 11 | >4 | R | 2 |
| Cefquinom | ≤2 | S | 13 | |||
| Ceftiofur | =2 | S | 13 | |||
| Cephalothin | ≤1 | S | 13 | |||
| Clindamycin | ≤0.125 | S | 13 | |||
| Colistin | >2 | R | 13 | |||
| Doxycyclin | ≤0.125 | S | 13 | |||
| Enrofloxacin | =0.625 | S | 13 | |||
| Erythromycin | ≤0.125 | S | 13 | |||
| Florfenicol | =2 | S | 13 | |||
| Gentamicin | ≤1 | S | 13 | |||
| Neomycin | ≤8 | S | 12 | >16 | R | 1 |
| Nitrofurantoin | >64 | R | 13 | |||
| Oxacillin | ≥4 | R | 13 | |||
| Penicillin G-potassium | =0.25 | I | 13 | |||
| Rifampin | ≤0.0625 | S | 13 | |||
| Spectinomycin | =32 | S | 9 | =64 | I | 4 |
| Sulfamethoxazol/trimethoprim | ≤4.75/0.25 | S | 13 | |||
| Tetracycline | ≤0.25 | S | 13 | |||
| Tiamulin | ≤0.25 | S | 13 | |||
| Tilmicosin | =2 | S | 13 | |||
| Tulathromycin | ≤1 | S | 13 | |||
| Vancomycin | ≤0.5 | S | 13 |
Serological testing of alpacas originating from herds A, B and C using a commercial enzyme-linked immunosorbent assay (ELISA) based on a phospholipase D antigen (PLD ELISA) and an in-lab ELISA using a whole cell antigen (WCA ELISA). Serum samples from a total of 232 animals were tested.
| PLD ELISA | WCA ELISA | ||||
|---|---|---|---|---|---|
| Herd | Positive | Negative | Positive | Negative | Total |
| A | 110 (62.9%) | 65 (37.1%) | 124 (70.9%) | 51 (29.1%) | 175 (75.4%) |
| B | 8 (20.5%) | 31 (79.5%) | 8 (20.5%) | 31 (79.5%) | 39 (16.8%) |
| C | 12 (66.7%) | 6 (33.3%) | 10 (55.6%) | 8 (44.4%) | 18 (7.8%) |
| Total | 130 (56%) | 102 (44%) | 142 (61.2%) | 90 (38.8%) | 232 (100%) |
Comparative serological testing of samples taken from alpacas originating from herds A, B and C using a commercial ELISA based on a phospholipase D (PLD ELISA) and an in-lab ELISA using whole cell antigen (WCA ELISA). A total of 247 serum samples from 232 alpacas were tested.
| PLD ELISA | WCA ELISA | Total | |
|---|---|---|---|
| Positive | Negative | ||
| Positive | 131 (93.3%) | 5 (3.7%) | 136 (55.1%) |
| Negative | 21 (18.9%) | 90 (81.1) | 111 (44.9%) |
| Total | 152 (61.5%) | 95 (38.5%) | 247 (100%) |